MannKind Wins FDA Nod for Furoscix ReadyFlow, Expanding Heart Failure Treatment Options
Event summary
- MannKind's Furoscix ReadyFlow received FDA approval on July 24, 2026 for treating edema in adults with heart failure or chronic kidney disease.
- The autoinjector delivers an IV-equivalent dose of furosemide in under 10 seconds, offering a faster alternative to the existing On-body infusor.
- Furoscix ReadyFlow is expected to be commercially available by late August 2026.
- Heart failure affects 6.7 million adults in the U.S., with costs projected to reach $70 billion annually by 2030.
The big picture
MannKind's approval addresses a critical gap in managing fluid overload outside hospitals, aligning with broader trends toward decentralized care. The autoinjector could reduce the $70 billion annual cost burden of heart failure by minimizing emergency visits and hospitalizations. Success hinges on clinician adoption and payer support for this novel delivery method.
What we're watching
- Market Adoption
- How quickly cardiologists and nephrologists integrate Furoscix ReadyFlow into outpatient care protocols.
- Reimbursement Dynamics
- Whether payers cover the autoinjector given its potential to reduce hospitalizations.
- Competitive Positioning
- The pace at which MannKind can differentiate Furoscix ReadyFlow from existing diuretic therapies.